Cannavò S, Almoto B, Dall'Asta C, Corsello S, Lovicu R M, De Menis E, Trimarchi F, Ambrosi B
Department of Medicine and Pharmacology, University of Messina, Italy.
Eur J Endocrinol. 2003 Sep;149(3):195-200. doi: 10.1530/eje.0.1490195.
Since Cushing's disease due to large pituitary tumors is rare, we evaluated biochemical characteristics at entry and the results of first surgical approach and of adjuvant therapeutic strategies during a long-term follow-up period.
We studied 26 patients (nine male, 17 female; 42.5+/-12.7 years, mean+/-s.e.) with ACTH-secreting pituitary macroadenoma (tumor diameter: 11-40 mm).
At entry, plasma ACTH, serum cortisol and 24-h urinary free cortisol (UFC) levels were measured in all patients, a high-dose dexamethasone (dexa) suppression test was evaluated in 22 cases and a corticotrophin releasing hormone (CRH) test in 20 cases. Patients were re-evaluated after operation and, when not cured, they underwent second surgery, radiotherapy and/or ketoconazole treatment. The follow-up period was 78+/-10 months.
Before surgery, dexa decreased ACTH (>50% of baseline) in only 14/22 patients. The CRH-stimulated ACTH/cortisol response was normal in six patients, impaired in six patients and exaggerated in eight patients. After operation eight patients were cured, nine had normalized cortisol levels and nine were not cured. Pre-surgery, mean ACTH values were significantly higher in the not cured patients than in those normalized (P<0.05) and cured (P<0.01); the ACTH response to CRH was impaired in only six patients of the not cured group. The tumour diameter was significantly less in cured patients (P<0.02) and in normalized patients (P<0.05) than in the not cured ones. Magnetic resonance imaging (MRI) showed invasion of the cavernous sinus in 2/9 normalized, and in 6/9 not cured patients. After surgery, ACTH, cortisol and UFC were significantly lower than at entry in cured and in normalized patients, but not in not cured patients. In the cured group, the disease recurred in one patient who was unsuccessfully treated with ketoconazole. In the normalized group, a relapse occurred in eight patients: radiotherapy and ketoconazole induced cortisol normalization in one case, hypoadrenalism in one case and were ineffective in another one, while five patients were lost at follow-up. In the not cured group, eight patients underwent second surgery, radiotherapy and/or ketoconazole, while one patient was lost at follow-up. These therapies induced cortisol normalization in two patients and hypoadrenalism in one.
(i) A sub-set of patients with ACTH-secreting pituitary macroadenoma showed low sensitivity to high doses of dexamethasone and to CRH, (ii) pituitary surgery cured Cushing's disease in a minority of patients, (iii) high baseline ACTH levels, impaired ACTH response to CRH, increased tumor size or invasion of the cavernous sinus were unfavourable prognostic factors for surgical therapy, and (iv) second surgery, radiotherapy and/or ketaconazole cured or normalized hypercortisolism in half of the patients with recurrence or not cured.
由于因垂体大腺瘤导致的库欣病较为罕见,我们评估了患者初诊时的生化特征、首次手术治疗的结果以及长期随访期间辅助治疗策略的效果。
我们研究了26例分泌促肾上腺皮质激素(ACTH)的垂体大腺瘤患者(9例男性,17例女性;平均年龄42.5±12.7岁),肿瘤直径为11 - 40毫米。
所有患者初诊时均检测血浆ACTH、血清皮质醇和24小时尿游离皮质醇(UFC)水平;22例患者进行了高剂量地塞米松(dexa)抑制试验,20例患者进行了促肾上腺皮质激素释放激素(CRH)试验。术后对患者进行重新评估,未治愈的患者接受二次手术、放疗和/或酮康唑治疗。随访期为78±10个月。
手术前,仅14/22例患者的dexa使ACTH降低(>基线的50%)。6例患者CRH刺激后的ACTH/皮质醇反应正常,6例受损,8例亢进。术后8例患者治愈,9例患者皮质醇水平恢复正常,9例未治愈。术前,未治愈患者的平均ACTH值显著高于皮质醇水平恢复正常的患者(P<0.05)和治愈患者(P<0.01);未治愈组中仅6例患者对CRH的ACTH反应受损。治愈患者和皮质醇水平恢复正常患者的肿瘤直径显著小于未治愈患者(P<0.02和P<0.05)。磁共振成像(MRI)显示,皮质醇水平恢复正常的9例患者中有2例以及未治愈的9例患者中有6例海绵窦受侵。术后,治愈患者和皮质醇水平恢复正常患者的ACTH、皮质醇和UFC显著低于初诊时,但未治愈患者无此变化。在治愈组中,1例患者疾病复发,酮康唑治疗无效。在皮质醇水平恢复正常组中,8例患者复发:放疗和酮康唑治疗使1例患者皮质醇恢复正常,1例发生肾上腺功能减退,1例无效,5例失访。在未治愈组中,8例患者接受了二次手术、放疗和/或酮康唑治疗,1例失访。这些治疗使2例患者皮质醇恢复正常,1例发生肾上腺功能减退。
(i)一部分分泌ACTH的垂体大腺瘤患者对高剂量地塞米松和CRH敏感性较低;(ii)垂体手术仅使少数患者的库欣病得以治愈;(iii)高基线ACTH水平、对CRH的ACTH反应受损、肿瘤增大或海绵窦受侵是手术治疗的不良预后因素;(iv)二次手术、放疗和/或酮康唑使半数复发或未治愈患者的高皮质醇血症得到治愈或恢复正常。